Using the 340B Drug Pricing Program to Support Primary Care-Based Hepatitis C Treatment in a Safety-Net Hospital Patient-Centered Medical Home
Over 2 million people in the US had chronic hepatitis C (HCV) infection during 2013- 2016, and HCV remains a leading cause of morbidity and mortality in the United States. Expanding HCV treatment in primary care would improve treatment access and follow-up but is resource intensive, requiring significant staff support. Using a budget impact analysis, a new study […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.